GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Long-Term Debt

Endonovo Therapeutics (Endonovo Therapeutics) Long-Term Debt : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Long-Term Debt?

Endonovo Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.


Endonovo Therapeutics Long-Term Debt Historical Data

The historical data trend for Endonovo Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Long-Term Debt Chart

Endonovo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Endonovo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Endonovo Therapeutics  (OTCPK:ENDV) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Endonovo Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367